EMT-6 Xenograft Model Service for Breast Cancer

The EMT-6 xenograft model offers a highly proliferative and immunogenic in vivo environment, making it an essential tool for evaluating both conventional chemotherapies and modern immuno-oncology agents in breast cancer research. Alfa Cytology provides an end-to-end EMT-6 xenograft model service, utilizing optimized inoculation protocols and comprehensive downstream analysis to ensure your preclinical candidates are tested with the highest degree of scientific accuracy.

Overview of EMT-6 Xenograft Model for Breast Cancer

The EMT-6 cell line is a murine mammary carcinoma model originally derived from a transplantable tumor in a BALB/c mouse. While it can be used as a syngeneic model, its application as a xenograft in immunocompromised hosts allows researchers to focus specifically on tumor cell intrinsic responses and pharmacokinetics. EMT-6 is recognized for its rapid growth kinetics and its tendency to form dense, well-vascularized tumors in vivo.

The EMT-6 model exhibits a distinct microenvironment characterized by regions of low oxygenation, which closely mimics the physiological conditions found in many human solid tumors. This makes it a preferred choice for testing hypoxia-activated prodrugs and radiotherapy enhancers. Furthermore, its high tumorigenicity and consistent growth patterns make it a robust platform for high-throughput efficacy screening of novel cytotoxic agents.

Fig 1. Fulvestrant combined with N-803 decreases triple-negative breast cancer (TNBC) tumor growth in vivo. (Wolfson B, et al., 2021)

Cell Line Information: EMT-6

The EMT-6 cell line is characterized by its epithelial morphology and aggressive growth characteristics both in vitro and in vivo.

Alfa Cytology's team of oncology experts subjects all cell lines to rigorous STR profiling and mycoplasma screening to ensure their identity accuracy and purity. By partnering with Alfa Cytology, you can fully leverage our specialized technical expertise in establishing EMT-6 models, thereby ensuring the reproducibility and scientific rigor of your experimental results.

Our Services

Workflow of EMT-6 Xenograft Model Construction

Alfa Cytology follows a standardized and ethically compliant workflow to establish the EMT-6 xenograft model:

• Cell Preparation: EMT-6 cells are cultured in optimized growth media and harvested during the exponential growth phase. We verify cell viability and concentration to ensure a standardized inoculum.
• Host Selection & Acclimatization: Healthy immunocompromised mice (such as Nude or SCID strains) are selected and allowed to acclimate to our controlled laboratory environment to ensure physiological stability before the study begins.
• Inoculation Procedure: A high-viability suspension of EMT-6 cells is prepared, often supplemented with a biological matrix carrier to enhance initial engraftment. The cells are precisely injected in vivo via subcutaneous or orthotopic mammary fat pad routes.
• Systematic Monitoring: Following inoculation, tumor growth is systematically tracked. We use precision calipers to record tumor dimensions and monitor animal body weight, establishing a reliable growth curve that adheres to strict welfare guidelines.
• Randomization & Dosing: Once tumors reach a consistent and statistically relevant growth threshold, animals are randomized into treatment and control groups to ensure balanced distribution before therapeutic dosing commences.

Fig 2. EMT-6 Xenograft Model Construction Workflow

Case Study - EMT-6 Xenograft Model Development

In a recent validation study conducted at Alfa Cytology, the EMT-6 xenograft model was utilized to evaluate the efficacy of a novel anti-angiogenic agent. The model demonstrated robust engraftment and a highly uniform growth rate across all study cohorts, providing a clear window for observing therapeutic effects. The in vivo data revealed a significant reduction in tumor volume and a decrease in vascular density within the treatment group.

Why Choose Alfa Cytology?

• Exceptional Take Rates: Optimized inoculation techniques that ensure reliable tumor establishment.
• Microenvironment Expertise: Specialized knowledge in evaluating models with hypoxic characteristics.
• Technical Precision: Consistent, high-frequency monitoring for precise growth kinetic data.
• Comprehensive Support: Full range of endpoint services, including PK/PD analysis and histopathology.

Contact Us

Are you looking to accelerate your breast cancer research with the robust EMT-6 xenograft model? Please reach out to us today to discuss your project parameters, or contact us directly to request a comprehensive consultation and quote.

For research use only. Not intended for any clinical use.